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Introduction
• Peptides	as	potential	drugs:	
Successful	chemical	synthesis	of	oxytocin	by	
duVigneaud in	1953
• over	a	hundred	peptide	drug	candidates	are	in	
development	for	a	wide	variety	of	diseases
• Peptides	differ	from	proteins:	
smaller	and	typically	lack	a	defined	tertiary	structure
Introduction
• Amino	acids	linked	to	each	other	by	peptide	bonds
• Peptide	bond	occurs	when	nitrogen	atom	on	one	amino	
acid	binds	to	the	carboxyl	group	of	another	amino	acid.
What	is	peptide	and	peptide	bond	?
• Malavolta (2011)
Peptides	are	molecules	containing	fewer	than	40	
amino	acid	residues,	while	proteins	contain	50	
residues	or	more
• Lee	(1991)	
Amino	acids	joined	together	in	chains	of	50	amino	
acids	or	less	are	defined	as	peptides,	50-100	
amino	acids	are	defined	as	polypeptides,	and	over	
100	amino	acids	are	defined	as	proteins
Definition	of	Peptide
Tyr
Lys
Arg
Ser
Trp
Asp
Glu
Gln
Met
Amino	Acid	Building	Block
• A	number	of	hormones,	enzymes,	antitumor	
agents,	antibiotics	and	neurotransmitters	are	
peptides.
• Peptides	regulate	many	physiological	processes,	
acting	at	some	sites	as	endocrine	or	paracrine
signals	and	at	other	sites	as	neurotransmitters	or	
growth	factors.	
• Nowadays,	peptides	are	used	as	therapeutic	
agents	against	diverse	disease	areas	such	as	
neurological,	endocrinological and	hematological	
disorders
Purposes	of	Peptides
Table	1	Several	peptide-based	parenteral	
products	in	the	market	in	2010-2013
Generic	
name
Trade	name Supplier Dosage	form	 Shelf-life	
and	storage	
temp.
pH
Thyrotropine	releasing	hormones
TRH/TRF Relefact TRH® Sanovi-
Aventis
Liquid	inj. 2	yr		15-
25°C
6.5
Antibiotic	peptides
Daptomycin Cubicin® Novartis Powder	for	inj. 3	yr,	2°C	–
8°C
4-5
Teicoplanin Targocid® Sanofi-
Aventis
Powder	for	inj. 4	yr,	2-8°C
Platelet	aggregates	inhibitors
Eptifibatide Integrilin® GlaxoSmithKl
ine
Liquid	for	
infusion	
3	yr,	2-8°C 5.35
Somatostatin		analog
Octreotide	
acetate
Sandostatin®		 Novartis Liquid	inj. 3		yr,	2-8°C 4.2
Vasopressins	and	analogs
Desmopressin	 DDAVP® Ferring Liquid	inj. 4	yr,	2-8°C 4-5
Octostim® Ferring Liquid	inj. 4	yr,	2-8°C 4
Minrin® Ferring Liquid	inj. 4	yr,	2-8°C 4
Felypressin Citanest	3%	
Octapressin®
Densply Liquid	inj. 3	yr,	15-25°C 3.5-
5.2
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Table	1	Several	peptide-based	parenteral	
products	in	the	market	in	2010-2013
Generic	
name
Trade	name Supplier Dosage	form	 Shelf-life	
and	storage	
temp.
pH
Oxytocins
Oxytocin Syntocinon® Defiante Liquid	inj. 4	yr,	2-8°C 4
Carbetocin Pabal® Ferring Liquid	inj. 2	yr,		2-8°C 3.8
Oxytocin	antagonist
Atosiban Tractocile® Ferring Liquid	inj. 4yr,	2-8°C 4.5
Tractocile® Ferring Liquid	inj. 4	yr	2-8°C 4.5
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Table	1	Several	peptide-based	parenteral	
products	in	the	market	in	2010-2013
Generic	
name
Trade	name Supplier Dosage	form	 Shelf-life	
and	storage	
temp.
pH
GNRH/LHRH	agonists
Goserelin Zoladex® Div Liquid	inj. 3	yr,		<	25°C
Gonadorelin Relefact	
LH-RH®
Sanofi-
Aventis
Liquid	inj. 15-25°C
Triptorelin Decapeptyl	-
CR®	
Ipsen Powder	and	
solv.	for	sol	for	
inj.	
3	yr,	2-8°C
Nafarelin	 Synarel® Pfizer Liquid	nasal	
spray
2	yr,	<	25°C 5-7
Leuprolide Eligard	®	 Sanofi-
Aventis
Powder	and	
solv.	for	sol	for	
inj.
2	yr,	2-8°C
Cetrorelix Cetrotide® Serono Powder	for	inj. 3	yr,	15-
25°C
Table	1	Several	peptide-based	parenteral	
products	in	the	market	in	2010-2013
Generic	
name
Trade	name Supplier Dosage	form	 Shelf-life	
and	storage	
temp.
pH
Non-NSAID analgesic
Ziconotide Prialt® Elan Liquid	inj. 3	yr,		2-8°C 4-5
Calcitonins
Salmon	
Calcitonin
Calcitonin	
Sandoz®
Novartis Liquid		inj. 5	yr,		2-8°C 3-5
Human	parathyroid	hormone	[hPTH	(1–34)]
Teriparatide	 Forsteo® Eli	Lily Liquid	inj. 2	yr,		2-8°C
Fusion	inhibitor	of	HIV-1	with	CD4	cells
Enfuvirtide Fuzeon® Roche Powder	and	
solv. solution	
for	inj.
4	yr,		2-8°C
ACTH	and	derivatives
CRH/CRF/
Corticorelin
CRH	-
Ferring®
Ferring Powder	for	inj. 3	yr,	<	25°C
• The	sensitivity	to	enzymatic	breakdown	
• The	poor	ability	to	pass	absorbing	membranes	
typically	results	in	a	poor	bioavailability	
following		non-parenteral administration.	
• The	lack	of	physical	and	chemical	stability	lead	
to	significant	degradation	during	processing	
and	storage	of	the	(aqueous)	formulations
Pharmaceutical	peptides:	
Challenge
• buccal,
• rectal,
• vaginal,
• percutaneous,
• ocular,
• transdermal,
• nasal,
• pulmonary	
many	of	these	routes	of	administration	are	still	under	
investigation	and	they	may	be	insufficiently	efficient,	
especially	when	a	rapid	effect	is	desired.	
Non-invasive	routes	for	peptide	
drug	administration
Intravenous	administration	is	the	most	
efficient	way	to	deliver	peptide	drugs	
directly	into	the	systemic	circulation
most peptide drugs have to be stored 
and transported at low temperatures
Chemical	degradation	pathways	
• hydrolysis,	
• oxidation,	
• deamidation .	
Physical	degradation:
• adsorption	
• aggregation	
better	understanding	of	the	underlying	mechanisms	of	instability	of	a	
certain	peptide to	design	rational	strategies	in	the	development	
process	of	pharmaceuticals	to	optimize	the	stability	of	the	peptide	in	
the	final	formulation	
problem	in	the	
development	as	active	
pharmaceuticals
Need
Peptide	Degradation
Pathways
Peptide	instability	and	the	
possible	causes	of	degradation
• Hydrolytic	pathways
– Chain	cleavage	of	the	peptide	backbone
– Deamidation	of	Asn	and	Gln	residues
– Isomerization	of	Asp	residues
• Oxidation	pathways
– Autoxidation
– Metal-catalyzed	oxidation
– Light-induced	oxidation
• β-elimination	reactions
• Disulfide	exchange	reactions
• Dimerization,	aggregation,	and	precipitation
Deamidation pathways	of	Asn residue	via	
A.	direct	hydrolysis	and	B.	succinimide mediation
Selected	oxidation	reactions	of	Met	and	His.	(A):	methionine	oxidation	by	peroxide	to	
methionine	sulfoxide in	acidic	solution	(HA=acid).	(B):	2-oxo-His,	Asn and	Asp	
(adapted	from	Li,	et.	al,	1995).
Oxytocin	degradation	pathways
Strategies	to	improve	peptide	stability	in	
liquid	formulations	
Degradation	pathway Stabilization	strategy Amino	acid	
residue(s)	
involved
Chemical	Instability
Acid/base	catalyzed	
hydrolysis
pH
buffer	species
co-solvents
Ser
Trp
Asn-Pro
Asn-Tyr
Deamidation pH	3-5
increased	solvent	viscosity
Asn,	Gln
β-elimination Buffer	species
divalent	metal	ions
Cys-Cys
Table 2 Degradation pathways and possible stabilization strategies for peptides 
including amino acid residues involved in the degradation.
Degradation	pathway Stabilization	strategy Amino	acid	
residue(s)	
involved
Chemical	Instability
Oxidation pH	<	7
air	exclusion
antioxidants
Trp,	Met,		Cys,	
Tyr,	His
Light	induced	oxidation Protect	from	light Trp
Metal	induced	oxidation Chelating	agents
Polyols
His,	Cys,	Arg,	Pro,	
Met
Disulfide	exchange Surfactans
Polyols	and	sugars
Buffer	and	divalent	metal	ions
Cys-Cys
Table 2 Degradation pathways and possible stabilization strategies for peptides 
including amino acid residues involved in the degradation, continued
Degradation	pathway Stabilization	strategy Amino	acid	
residue(s)	
involved
Physical	Instability
Dimerization	and	further	
aggregation
Lower	concentration
minimal	mechanical	stress
organic	solvents
alkyl	saccharide
alkyl	polyglycoside
Cys-Cys
Tyr-Tyr
Adsorption surfactans
polymers
His
Arg
Table 2 Degradation pathways and possible stabilization strategies for peptides 
including amino acid residues involved in the degradation, continued
Conclusion
• In aqueous solutions peptides are often unstable. 
• Peptides have unique structures that the side chain 
of nearly all of the amino acid residues are fully 
solvent exposed, allowing maximal contact with 
solvents 
• the degradation rates appear to correlate with the 
degree of solvent exposure. 
• Based on knowledge of the peptide’s structure and 
an understanding of the predominant degradation 
pathways, the strategies may be developed to 
achieve adequate stability of the formulation. 
• The degradation pathways of peptides are 
mainly dependent on the amino acid sequence. 
• The most prominent degradation pathways for 
peptides are hydrolysis, oxidation, and 
dimerization. 
• Formulating peptides in a specific pH with a 
specific buffer, avoiding oxygen reactive species, 
and minimizing solvent exposure eliminate 
chemical degradation. 
• Increasing solution viscosity by using sugars or 
polymers reduces peptide mobility and further 
decelerates physical degradation. 
Conclusion
Instability	is	the	most	stable	
characteristic	of	
a	dissolved	peptide
Christina	Avanti,	2011
Instabilities	are	a	natural	way	to	
achieve	thermodynamic	equilibrium
Christina	Avanti,	2012

